GSK plc stands to be the first to submit Phase III data to regulators for use of a respiratory syncytial virus (RSV) vaccine in adults 50-59, potentially broadening the adult market opportunity for the vaccine. Arexvy received US Food and Drug Administration approval in May for adults 60 and older almost simultaneously with Pfizer Inc.’s RSV vaccine Abrysvo. The vaccines are the first to reach the market for RSV lower respiratory tract disease, putting the two companies in a competitive commercial showdown.
Key Takeaways
- GSK’s Phase III data on Arexy showed non-inferior immune responses in adults 50-59 at increased risk for RSV due to certain medical conditions.
GSK announced positive preliminary results from its Phase III trial on 25 October, showing non-inferior immune responses observed in adults...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
